Methods: Panelists received thematic topics and relevant literature prior to the meeting. Statements on how to interpret response and progression on therapy in PCa with PSMA PET/CT and when to use it were developed. Panelists voted anonymously on a nine-point scale, ranging from strongly disagree (1) to strongly agree (9). Median scores described agreement and consensus.
Results: PSMA PET/CT consensus statements concerned utility, best timing for performing, criteria for evaluation of response, patients who could benefit, and handling of radiolabeled PSMA PET tracers. Consensus was reached on all statements. PSMA PET/CT can be used before and after any local and
systemic treatment in patients with metastatic disease to evaluate response to treatment. Ideally, PSMA PET/CT imaging criteria should categorize patients as responders, patients with stable disease, partial response, and complete response, or as non-responders. Specific clinical scenarios such as oligometastatic or polymetastatic disease deserve special consideration.
Conclusions: Adoption of PSMA PET/CT should be supported by indication for appropriate use and precise criteria for interpretation. PSMA PET/CT criteria should categorize patients as responders or nonresponders. Specific clinical scenarios deserve special consideration.
|Number of pages||8|
|Journal||European Journal of Nuclear Medicine and Molecular Imaging|
|Early online date||2 Jul 2020|
|Publication status||E-pub ahead of print - 2 Jul 2020|
- Oligometastatic Prostate Cancer
- PERCIST; PET/CT
- Polymetastatic Prostate Cancer
- Prostate Cancer
- Prostate-Specific Membrane Antigen (PSMA)
- PSMA Ligand
- Oligometastatic prostate cancer
- Prostate-specific membrane antigen (PSMA)
- PSMA ligand
- MEMBRANE ANTIGEN
- EUROPEAN ORGANIZATION
- Polymetastatic prostate cancer
- Prostate cancer